Background: The Italian severe/uncontrolled asthma (SUA) web-based registry encompasses demographic, clinical, functional, and inflammatory data; it aims to raise SUA awareness, identifying specific phenotypes and promoting optimal care. Methods: Four hundred and ninety three adult patients from 27 Italian centers (recruited in 2011-2014) were analyzed. Results: Mean age was 53.8 years. SUA patients were more frequently female (60.6%), with allergic asthma (83.1%). About 30% showed late onset of asthma diagnosis/symptoms (>40 years); the mean age for asthma symptoms onset was 30.2 years and for asthma diagnosis 34.4 years. 97.1% used ICS (dose 2000 BDP), 93.6% LABA in association with ICS, 53.3% LTRAs, 64.1% anti-IgE, 10.7% theophylline, and 16.0% oral corticosteroids. Mean FEV1% pred of 75.1%, median values of 300/mm3 of blood eosinophil count, 323 kU/L of serum total IgE, and 24 ppb of FENO were shown. Most common comorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasal polyposis (30.2%), and allergic conjunctivitis (30.2%). 55.7% of SUA patients had exacerbations in the last 12 months, 9.7% emergency department visits, and 7.3% hospitalizations. Factors associated with exacerbation risk were obesity (OR, 95% CI 2.46, 1.11-5.41), psychic disorders (2.87, 0.89-9.30—borderline), nasal polyps (1.86, 0.88-3.89—borderline), partial/poor asthma treatment adherence (2.54, 0.97-6.67—borderline), and anti-IgE use in a protective way (0.26, 0.12-0.53). Comparisons to severe asthma multicenter studies and available registries showed data consistency across European and American populations. Conclusions: An international effort in the implementation of SUA patients’ registries could help to better understand the clinical features and to manage severe asthma, representing a non-negligible socioeconomic burden for health services.

RItA: The Italian severe/uncontrolled asthma registry

Latorre, M.;Paggiaro, P.;Carrozzi, L.;Pistelli, F.;
2018-01-01

Abstract

Background: The Italian severe/uncontrolled asthma (SUA) web-based registry encompasses demographic, clinical, functional, and inflammatory data; it aims to raise SUA awareness, identifying specific phenotypes and promoting optimal care. Methods: Four hundred and ninety three adult patients from 27 Italian centers (recruited in 2011-2014) were analyzed. Results: Mean age was 53.8 years. SUA patients were more frequently female (60.6%), with allergic asthma (83.1%). About 30% showed late onset of asthma diagnosis/symptoms (>40 years); the mean age for asthma symptoms onset was 30.2 years and for asthma diagnosis 34.4 years. 97.1% used ICS (dose 2000 BDP), 93.6% LABA in association with ICS, 53.3% LTRAs, 64.1% anti-IgE, 10.7% theophylline, and 16.0% oral corticosteroids. Mean FEV1% pred of 75.1%, median values of 300/mm3 of blood eosinophil count, 323 kU/L of serum total IgE, and 24 ppb of FENO were shown. Most common comorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasal polyposis (30.2%), and allergic conjunctivitis (30.2%). 55.7% of SUA patients had exacerbations in the last 12 months, 9.7% emergency department visits, and 7.3% hospitalizations. Factors associated with exacerbation risk were obesity (OR, 95% CI 2.46, 1.11-5.41), psychic disorders (2.87, 0.89-9.30—borderline), nasal polyps (1.86, 0.88-3.89—borderline), partial/poor asthma treatment adherence (2.54, 0.97-6.67—borderline), and anti-IgE use in a protective way (0.26, 0.12-0.53). Comparisons to severe asthma multicenter studies and available registries showed data consistency across European and American populations. Conclusions: An international effort in the implementation of SUA patients’ registries could help to better understand the clinical features and to manage severe asthma, representing a non-negligible socioeconomic burden for health services.
2018
Maio, Sonia; Baldacci, S.; Bresciani, M.; Simoni, M.; Latorre, M.; Murgia, N.; Spinozzi, F.; Braschi, M.; Antonicelli, L.; Brunetto, B.; Iacovacci, P....espandi
File in questo prodotto:
File Dimensione Formato  
Maio_et_al-2018-Allergy.pdf

solo utenti autorizzati

Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 499.75 kB
Formato Adobe PDF
499.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/939459
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 50
social impact